A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

NCT07221188 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1250

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-alcoholic Fatty Liver Disease

Interventions

DRUG: Efimosfermin Alfa
DRUG: Placebo

Sponsor

GlaxoSmithKline